Skip to content

Microangiopathy in Diabetes

Microangiopathy IN Diabetes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07145567
Acronym
MIND
Enrollment
400
Registered
2025-08-28
Start date
2024-03-01
Completion date
2027-12-31
Last updated
2025-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Microangiopathy, Microvascular Complications

Keywords

Laser speckle contrast imaging, Spatial frequency domain imaging, Laser doppler flowmetry, Iontophoresis, Local thermal hyperemia, Post occlusive reactive hyperemia

Brief summary

This clinical trial aims to evaluate the use of a contactless and non-invasive technique to measure the properties of the skin's microcirculation and its regulatory functions in both healthy individuals and patients with microvascular disease associated with type 1 diabetes. It is hoped that the study results will lead to the development of a useful method for detecting diabetic complications at an early stage, thereby enabling treatment and preventive measures before the onset of severe microangiopathy.

Detailed description

This study will employ investigational devices to evaluate microvascular function and correlate it to degree of microangiopathy in persons with diabetes type 1 and healthy controls. The investigational device, TCI P4, is a novel, contactless, non-invasive, non-CE marked, class IIa Spatial Frequency Domain Imaging (SFDI) system. The device utilizes an LED light projector to cast patterned, multi-wavelength light onto the skin while multiple cameras capture narrow-band reflections. This method yields two-dimensional data on skin structure and molecular composition (including hemoglobin, oxygen, and water). Established comparators such as laser speckle contrast imaging (LSCI) and the EPOS system are employed to benchmark device performance and validate measurements.

Interventions

None listed

Sponsors

Neko Health AB
CollaboratorUNKNOWN
Karolinska Institutet
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Diabetes mellitus type 1. * Cohort specific inclusion criteria apply, please review 'groups' section.

Exclusion criteria

* Patients unable to understand patient information due to cognitive impairment. * Patients unable to understand patient information due to language barriers. * Ongoing acute infection disease or inflammatory condition. * Pregnant or breast-feeding women. * Patients with damaged and/or scarred tissue in the areas of interest for the investigational or comparator devices.

Design outcomes

Primary

MeasureTime frameDescription
Peak perfusion in response to local thermal hyperemiaInvestigation will take within 1 day from enrollment.As measured with investigational devices TCI P4, Pericam LSCI and EPOS devices.

Secondary

MeasureTime frameDescription
Perfusion heterogeneity in sole of feetInvestigation will take place within 1 day from enrollment.Perfusion heterogeneity index as measured by investigational device TCI P4. It will be stated as a numerical ordinal scale.

Countries

Sweden

Contacts

Primary ContactSara Tehrani, Medical Doctor
sara.tehrani@ki.se+46 08 123 550 00
Backup ContactJacob Widaeus, Medical Doctor
jacob.widaeus@ki.se+46 08 123 596 01

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026